Syndax Pharmaceuticals

Update in progress

SNDX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Syndax Pharmaceuticals is a commercial-stage biopharma company focused on cancer therapies. Its lead candidates include Revuforj (revumenib), a menin inhibitor for relapsed or refractory acute leukemias, and Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody for chronic graft-versus-host disease. The firm also pursues revumenib for mNPM1 AML and other leukemias, metastatic colorectal cancer, axatilimab for idiopathic pulmonary fibrosis, and Entinostat, a Class I HDAC inhibitor, under license from Eddingpharm. Based in New York since 2005.

Company score

Sentiment: 0.18; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive